Research programme: cell therapy - Angiocrine Bioscience

Drug Profile

Research programme: cell therapy - Angiocrine Bioscience

Alternative Names: E-CEL PEC™; E-CEL TEC™; E-CEL UVEC™

Latest Information Update: 15 Sep 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Angiocrine Bioscience
  • Class Cell therapies; Gene therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Chronic obstructive pulmonary disease; Haematological malignancies; Sickle cell anaemia; Tendon injuries

Most Recent Events

  • 15 Sep 2016 Preclinical trials in Chronic obstructive pulmonary disease in USA (Parenteral)
  • 15 Sep 2016 Preclinical trials in Haematological malignancies in USA (Parenteral)
  • 15 Sep 2016 Preclinical trials in Sickle cell anaemia in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top